Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Combination of antibiotics can cure Chlamydia-induced ReA: Study

Researchers from University of South Florida College of Medicine found a combination of antibiotics to be an effective treatment for Chlamydia-induced reactive arthritis, a major step forward in the management, and possibly cure, of this disease. Results of this study are published in the May issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

29 Apr 2010

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.

29 Apr 2010

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Salix Pharmaceuticals, Ltd. today announced plans for the Hepatic Encephalopathy Living Program (H.E.L.P.). H.E.L.P. is a first-of-its-kind patient and health care provider support program for the management of hepatic encephalopathy (HE) and will launch on May 24, 2010. The program will provide patients with HE educational materials, co-pay assistance, treatment adherence support and a 24-hour toll-free hotline.

27 Apr 2010

Rib-X Pharmaceuticals to demonstrate three presentations at Antibacterial Drug Development Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced that it will be presenting three separate presentations at the Cambridge Healthtech Institute's 4th Annual Antibacterial Drug Development Conference, Resistance is Futile: The Challenge of Antibacterial Drug Development, April 27 - 28, in San Diego, CA.

27 Apr 2010

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

ViroPharma Incorporated today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema.

27 Apr 2010

Fever in kids underestimated by Doctors: new study

In a new study researchers have found that some physicians may be missing the seriousness of an infection in a child presenting with fever. The study published in the British Medical Journal involved 16,000 children from 2004 to 2006 with fever and found that doctors could not diagnose up to one third of the potentially life-threatening illnesses in these children.

27 Apr 2010

Anacor Pharmaceuticals, MMV partner to discover and develop promising new malaria therapeutics

Anacor Pharmaceuticals today announced that it has entered into a research agreement with not-for-profit Medicines for Malaria Venture (MMV) to explore Anacor's novel boron chemistry platform for developing new therapeutics for the treatment of malaria. Under the agreement, Anacor will be responsible for leading the research effort and MMV will contribute its extensive malaria drug research expertise as well as financial support.

26 Apr 2010

Driving evolution of antibiotic resistance backwards

The use of antibiotics to treat bacterial infections causes a continual and vicious cycle in which antibiotic treatment leads to the emergence and spread of resistant strains, forcing the use of additional drugs leading to further multi-drug resistance.

26 Apr 2010

New method helps study interactions needed for formation of lipopolysaccharides

Scientists have combined chemistry and biology research techniques to explain how certain bacteria grow structures on their surfaces that allow them to simultaneously cause illness and protect themselves from the body's defenses.

26 Apr 2010

McGill researchers receive $1.7M for 10 cutting-edge research projects

Ten McGill University researchers received an important boost today, by way of the announcement of $1.7 million in new funding awarded through the Canada Foundation for Innovation's Leaders Opportunity Fund. "CFI investments are critical for our research leaders, to ensure that their research remains innovative and second to none," said Dr. Rima Rozen, Interim Vice-Principal (Research and International Relations) at McGill.

24 Apr 2010

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company, announced today the launch of its newest service for the admixture and delivery of Hibernation Therapeutics' patented Adenocaine™ microplegia, the world's first low-potassium, non-depolarizing cardioplegia solution.

From B. Braun Melsungen AG 23 Apr 2010

Complaint regarding Dragon Pharma's proposed merger with Datong Investment filed

Dragon Pharmaceutical Inc. announced today that a complaint regarding its proposed merger with Datong Investment Inc was filed in the Circuit Court of the Fifteenth Judicial Circuit for Palm Beach County, State of Florida, against the Company, and its eight directors.

23 Apr 2010

Dehaier Medical Systems announces initial public offering

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical products in China, announced today its initial public offering of 1,500,000 ordinary shares at $8.00 per share. The ordinary shares will begin trading today under the ticker symbol "DHRM" on the Nasdaq Capital Market.

23 Apr 2010

Acacia Research reports record first-quarter license fee revenues of $39.77M

Acacia Research Corporation today reported results for the three months ended March 31, 2010.

23 Apr 2010

International Day for Fighting Infection focuses on hospital infection control

Hospital acquired infections are the focus for the 3rd International Day for Fighting Infection, being marked on St. George’s Day, as experts meet to look at the evolution of infection control in hospitals.

22 Apr 2010

Resonant activation can be a strategy against bacterial persistence: Virginia Tech biologist

A Virginia Tech biologist proposes to use a physics strategy called resonant activation to nudge dormant bacteria cells into a stage where they will be sensitive to antibiotics.

22 Apr 2010

Bacterial infections often missed in febrile children in the ER

In a new study researchers reveal that up to one third of children with fever due to bacterial infections do not receive antibiotics in the emergency department and 20% of kids receive antibiotics unnecessarily.

22 Apr 2010

Initial results of gallium-containing compound to treat serious infection presented at AACR 2010

Genta Incorporated today announced the presentation of initial results from the first human use of a gallium-containing compound to treat serious infection. In a patient with cystic fibrosis and a highly resistant lung infection, who has been treated over a 2-year period, high concentrations of gallium were achieved in sputum.

21 Apr 2010

New study quantifies prevalence of MRSA infections in different patient populations

A multi-center study led by a researcher at Rhode Island Hospital has determined that long-term elder care, HIV-infected and hemodialysis patients are at increased risk of carrying methicillin-resistant Staphylococcus aureus (MRSA) in their nose.

21 Apr 2010

Resistance to antibiotics on the increase in intestinal bacteria in animals: Study

Anne-Mette R. Grønvold has through her doctoral research shown that resistance to antibiotics is on the increase in intestinal bacteria in animals as a direct result of antibiotic treatments. The antibiotics also alter the composition of bacteria in the intestines.

19 Apr 2010

Antibiotic News and Research

Further Reading

Combination of antibiotics can cure Chlamydia-induced ReA: Study

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Rib-X Pharmaceuticals to demonstrate three presentations at Antibacterial Drug Development Conference

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

Fever in kids underestimated by Doctors: new study

Anacor Pharmaceuticals, MMV partner to discover and develop promising new malaria therapeutics

Driving evolution of antibiotic resistance backwards

New method helps study interactions needed for formation of lipopolysaccharides

McGill researchers receive $1.7M for 10 cutting-edge research projects

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Complaint regarding Dragon Pharma's proposed merger with Datong Investment filed

Dehaier Medical Systems announces initial public offering

Acacia Research reports record first-quarter license fee revenues of $39.77M

International Day for Fighting Infection focuses on hospital infection control

Resonant activation can be a strategy against bacterial persistence: Virginia Tech biologist

Bacterial infections often missed in febrile children in the ER

Initial results of gallium-containing compound to treat serious infection presented at AACR 2010

New study quantifies prevalence of MRSA infections in different patient populations

Resistance to antibiotics on the increase in intestinal bacteria in animals: Study

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News